← Back to Search

Unknown

ONO-2020 for Healthy Participants

Phase 1
Waitlist Available
Research Sponsored by Ono Pharmaceutical Co. Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up part a, c and d: from day 1 up to day 7, part b and e: from day 1 up to day 21
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and tolerated by healthy adults, including elderly and Japanese participants. They will also study how the new drug is affected by food.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~part a, c and d: from day 1 up to day 7, part b and e: from day 1 up to day 21
This trial's timeline: 3 weeks for screening, Varies for treatment, and part a, c and d: from day 1 up to day 7, part b and e: from day 1 up to day 21 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
12-lead electrocardiograms (ECGs) parameters, such as but not limited to heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)
Clinical laboratory abnormalities (hematology, clinical chemistry, coagulation, and urinalysis)
Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)
+9 more
Secondary outcome measures
Pharmacokinetics (AUCinf in plasma)
Pharmacokinetics (AUClast in plasma)
Bacteriuria
+8 more

Trial Design

16Treatment groups
Experimental Treatment
Group I: Part E: Cohort E2 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
Group II: Part E: Cohort E1 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
Group III: Part D: Cohort D1 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Single dose of ONO-2020 orally in elderly healthy volunteers
Group IV: Part C: Cohort C2 ONO-2020Experimental Treatment1 Intervention
Single dose of ONO-2020 orally for CSF sampling
Group V: Part C: Cohort C1 ONO-2020Experimental Treatment1 Intervention
Single dose of ONO-2020 orally for CSF sampling
Group VI: Part B: Cohort B5 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Multiple ascending doses of ONO-2020 orally for 14 days
Group VII: Part B: Cohort B4 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Multiple ascending doses of ONO-2020 orally for 14 days
Group VIII: Part B: Cohort B3 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Multiple ascending doses of ONO-2020 orally for 14 days
Group IX: Part B: Cohort B2 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Multiple ascending doses of ONO-2020 orally for 14 days
Group X: Part B: Cohort B1 ONO-2020 or PlaceboExperimental Treatment2 Interventions
Multiple ascending doses of ONO-2020 orally for 14 days
Group XI: Part A: Cohort A6 ONO-2020 or Placebo - fastedExperimental Treatment2 Interventions
Single ascending doses of ONO-2020 orally under fasted conditions
Group XII: Part A: Cohort A5 ONO-2020 or Placebo - fastedExperimental Treatment2 Interventions
Single ascending doses of ONO-2020 orally under fasted conditions
Group XIII: Part A: Cohort A4 ONO-2020 or Placebo - fasted and fedExperimental Treatment2 Interventions
Single ascending doses of ONO-2020 orally under fasted and fed conditions
Group XIV: Part A: Cohort A3 ONO-2020 or Placebo - fastedExperimental Treatment2 Interventions
Single ascending doses of ONO-2020 orally under fasted conditions
Group XV: Part A: Cohort A2 ONO-2020 or Placebo - fasted and fedExperimental Treatment2 Interventions
Single ascending doses of ONO-2020 orally under fasted and fed conditions
Group XVI: Part A: Cohort A1 ONO-2020 or Placebo - fastedExperimental Treatment2 Interventions
Single ascending doses of ONO-2020 orally under fasted conditions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ONO-2020
2022
Completed Phase 1
~140
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Ono Pharmaceutical Co. LtdLead Sponsor
154 Previous Clinical Trials
94,531 Total Patients Enrolled
Project LeaderStudy DirectorOno Pharma USA Inc
12 Previous Clinical Trials
2,481 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities for patients to join this experiment?

"Indeed, the details of this clinical trial are currently being hosted on clinicaltrials.gov. It was initially posted on July 29th 2022 and has been refreshed as recently as August 16th 2022. 138 participants must be enrolled from a single location for this study to move forward."

Answered by AI

Has ONO-2020 been given permission from the FDA to be used in treatments?

"Due to the limited evidence of efficacy and safety, ONO-2020 is judged to be a 1 on our Risk Scale. This assessment reflects that it is in Phase 1 of clinical trials."

Answered by AI

How many participants can this experiment accommodate at maximum capacity?

"Affirmative. According to the clinicaltrials.gov listing, this experiment is currently attempting to find 138 individuals at one site. This trial was initially posted on July 29th 2022 and has been updated as of August 16th 2022."

Answered by AI

Who else is applying?

What state do they live in?
California
Mississippi
How old are they?
18 - 65
What site did they apply to?
Altasciences
What portion of applicants met pre-screening criteria?
Met criteria
~49 spots leftby Apr 2025